Quest Diagnostics (DGX) downgraded to a Hedgeye short with 20% downside risk as growth decelerates and valuation stays elevated. Hedgeye added Quest Diagnostics (DGX) as a new short idea, forecasting a potential 20% downside due to expected growth deceleration starting in Q2 2026. Analyst Tom Tobin noted that key growth drivers are lapping, signaling a bearish shift for the company. The call highlights a reversal from previous, more positive stances on the stock.
https://seekingalpha.com/news/4578775-quest-diagnostics-added-as-new-short-idea-at-hedgeye
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.